Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077894 · ClinicalTrials.gov registry record
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions
A clinical trial of Genetic Eye Disease, sponsored by National Eye Institute (NEI).
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT02077894 is a study of Genetic Eye Disease that is actively recruiting participants, run by National Eye Institute (NEI). The registered enrollment target is 2,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02077894, a study of Genetic Eye Disease, is actively recruiting participants, sponsored by National Eye Institute (NEI).
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective: The objective of this study is to identify genetic causes of inherited eye conditions through whole exome or whole genome sequencing (referred to as exome sequencing and genome sequencing in the remainder of the document). This includes identifying mutations in known genes or novel genes for recognized conditions, as well as identifying mutations in novel genes for previously uncharacterized genetic conditions involving the eye. Study Population: We plan to recruit 2,000 participants, to include both participants with an eye condition under study and unaffected family members. Ideally unaffected family members will be parents of an affected participant. Design: Participants will be self-referred or referred by an outside clinician. They will preferably be evaluated at the National Institutes of Health (NIH), but the option to participate offsite will be offered. Participants evaluated onsite will be recruited through other pre-existing NIH protocols, such as the National Eye Institute (NEI) Screening protocol (08-EI-0102), the NEI Ocular Natural History protocol (16-EI-0134), the Genetics of Inherited Eye Disease protocol (15-EI-0128), and the Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC) protocol (13-EI-0049). Offsite participants will be screened via phone or secure videoconference, and records will be requested for evaluation of affected participants. Both affected and unaffected eligible participants will undergo genetic counseling and will provide a blood sample and/or saliva sample for exome or genome sequencing. Biological relationships will be confirmed prior to exome or genome sequencing. Sequence data will be analyzed for primary variants and secondary findings, unless participants choose to opt-out of secondary analysis and reporting. All sequence variants deemed clinically relevant will be validated in a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory and the results will be returne
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2014-08-05 |
| Est. Completion | 2029-08-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02077894
The ClinicalTrials.gov registry entry for NCT02077894 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Genetic Eye Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02077894 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02077894 about?
NCT02077894 is a clinical study titled "Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions". Objective: The objective of this study is to identify genetic causes of inherited eye conditions through whole exome or whole genome sequencing (referred to as exome sequencing and genome sequencing in the remainder of the document). This includes identifying mutations in known genes or novel genes ...
What is the current status of trial NCT02077894?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2014-08-05. Estimated completion is 2029-08-05.
What conditions does trial NCT02077894 study?
This clinical trial studies the following conditions: Genetic Eye Disease.
Who is sponsoring clinical trial NCT02077894?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02077894 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.